KarinCA - prelinminary clinical trial results reported that ECOR was not substantially better STATISICALLY than the control in the primary clinical end point, but was statistically better than the control treatment in the secondary endpoints. ECOR seems to be at a crossroad...does it continue to press on with gammaCore headache clinical targets, reconsider pursuing bronchoconstriction, or choose some other clinical target for its vagus nerve stimulation therapy? 27 months after FDA approval and only now approaching a revenue run rate of $4M annually while incurring losses with a Class II device doesn't seem to justify a big move up. Current CEO & team inherited a mess and has a lot to think about. They deserve some more time to put forward a vision and path forward.
Market Data 
Markets 
AI
